Although these findings suggest a limitation of the usage of serum BDNF levels as a biomarker of AD for early diagnosis, potentiation of BDNF/TrkB signals will be a one of the therapeutic targets for the treatment of AD symptoms. Here, NTRK2 is linked to Alzheimer disease.